Nabriva appoints Dr David Chiswell as CEO
This article was originally published in Scrip
The Austrian biotechnology company Nabriva Therapeutics has appointed Dr David Chiswell as its chief executive officer. He succeeds George Golumbeski, who has left the company. Dr Chiswell has been involved with Nabriva since its foundation, having served as chairman of the supervisory board for the past three years. He founded and led Cambridge Antibody Technology from 1990 until 2002 (including as its CEO from 1996-2002). Since leaving CAT, Dr Chiswell has served on the boards of a number of biotech companies, including Arakis, Arrow Therapeutics, Daniolabs and Sosei. He currently serves as chairman of Albireo Pharma, a position which he will retain. Nabriva was founded in February 2006 as a spin-out of Sandoz.
You may also be interested in...
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.